This bill amends the Federal Food, Drug, and Cosmetic Act to facilitate the prompt approval of certain drugs, such as generics, by addressing issues related to proprietary safety information. It specifies that a drug will not be considered ineligible for approval or misbranded if its labeling omits safety information, including contraindications or warnings, that is protected by exclusivity periods or patents. This provision aims to prevent delays in market entry for these drugs while ensuring patient safety. The Secretary of Health and Human Services, through the FDA, is still mandated to require the inclusion of any appropriate safety information deemed necessary for the drug's safe use. The bill also clarifies that these changes do not affect the availability or scope of existing exclusivity protections or patent rights, except as explicitly stated.